中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

APPOINTMENT OF AUDITOR

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Reference is made to (i) the announcement of the Company dated 4 June 2026 in relation to, among other things, the poll results of the annual general meeting of the Company held on 4 June 2026 and the retirement of Moore CPA Limited ("**Moore**") as the auditor of the Company; and (ii) the supplemental announcement (collectively, the "**Announcements**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

APPOINTMENT OF AUDITOR

The Board hereby announces that, having considered the recommendation of the audit committee of the Company (the "**Audit Committee**"), it has resolved to appoint CCTH CPA Limited ("**CCTH**") as the new auditor of the Company to fill the casual vacancy following the retirement of Moore with effect from the date of approval by the Shareholders at the EGM (as defined below) and to hold office until the conclusion of the next annual general meeting of the Company.

ASSESSMENT OF CCTH

The Audit Committee has considered a number of factors in assessing the appointment of CCTH as the auditor, including but not limited to (i) CCTH's audit fee proposal; (ii) CCTH's extensive experience with over 40 listed companies, industry knowledge, and technical competence in providing audit work to listed companies, including those in the healthcare sector; (iii) its demonstrated independence from the Group, ensuring objectivity; (iv) its reputable standing in the market; (v) its resources and capabilities, including the size and structure of the proposed audit team; (vi) Guidelines for Effective Audit Committees – Selection, Appointment and Reappointment of Auditors published by the Accounting and Financial Reporting Council (the "**AFRC**"); and (vii) Guidance Notes on Change of Auditors published by the AFRC.

Based on the above, the Audit Committee has assessed and considered CCTH is eligible and suitable to act as the auditor of the Company for the consolidated financial statements of the Group for the year ending 31 December 2026. The Board and the Audit Committee are of the view that the appointment of CCTH as the auditor of the Company would maintain audit quality and enhance the effectiveness of the Company's annual audit and is in the interest of the Company and the shareholders as a whole.

The estimated audit fee for audit services as quoted by CCTH for the audit of the consolidated financial statements of the Company and its subsidiaries for the financial year ending 31 December 2026 is expected to be approximately RMB880,000 (exclusive of out-of-pocket expenses). The estimated audit fee has been determined after due consideration and arm's length negotiations between the Company and CCTH, taking into account, among other things, the size, nature and complexity of the Group's business operations, the expected scope of the audit, the audit timetable, and the level and mix of professional staff to be deployed.

The appointment of CCTH as the auditor of the Company is subject to the approval of the shareholders of the Company by way of an ordinary resolution at an extraordinary general meeting ("**EGM**"). A circular containing, among other things, details of the proposed appointment of CCTH as the auditor and a notice of the EGM will be despatched to the shareholders of the Company in due course.

The Board would like to take this opportunity to welcome CCTH as the auditor of the Company.

By order of the Board
China NT Pharma Group Company Limited
Chairman
Ng Tit

Hong Kong, 7 July 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.